The use of T cells as a potential treatment for cancer may not be broadly accepted by physicians, hospitals, patients, or the general public.

f894bc8f-69c2-4e1a-acf9-0db3a7396053

Veklury (remdesivir) was approved by the U.S. Food and Drug Administration in October 2020.

24261a9c-cc66-4b63-8210-33117ecbc846

If the FDA does not approve the drug in time, it could be written off as an unapproved product.

dfeda40c-70a2-4303-83c2-48f40b5a7f9f

GILEAD SCIENCES INC rely on third-party sites to collect patients’ white blood cells, known as apheresis centers.

0a30f950-1c7c-491c-943b-40efe9a82c3b

Federal and state budget pressures, as well as the annual grant cycles for federal andState funds, may cause purchasing patterns to not reflect patient demand for Yescarta.

7e4b75e4-e245-445a-994a-69ff100662b8

GILEAD SCIENCES INC sell and distribute most of its products in the United States exclusively through the wholesale channel.

4078c2d1-426c-487c-bdaa-30da601afd87

Successful commercialization depends in part on the availability of third-party payer reimbursement for the cost of such products.

0697d508-b53c-4723-8b39-746c65a9b180

Government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services.

9df33861-8425-4771-a574-d4472af6eb6f

Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on the company's business.

3990e6e3-9539-463a-8b76-b938de664f72

Third parties may illegally distribute and sell counterfeit versions of GIlead SCiENCes Inc's medicines.

d031e386-263f-4954-87b7-901bf32e285b

Counterfeit medicines pose a serious risk to patient health and safety.

e6f1c191-ff69-4da8-8403-e1a598ce0eab

GILEADS relies on independent third-party contract research organizations ("CROs") to perform most of its clinical studies.

ec28148e-66ae-462e-bcbe-a1e0013f3310

Any adverse developments affecting or resulting from GILEAD SCIENCES INC's manufacturing operations may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls.

61fb39e5-0b87-44c1-988c-904657a4522f

Manufacturing issues may cause delays in GIL's clinical trials and applications for regulatory approval.

ff6a271a-c487-483e-ba2a-6ff237ba6f38

GILEAD SCIENCES INC's operations depend on compliance with complex FDA and comparable international regulations.

667069a1-de0e-4737-9626-0914cf3bfce7

Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of GILE ADES' products.

7a25c76d-1ab9-4ac9-a27b-e6f8e8f80408

GILEAD SCIENCES INC's methodologies for calculations are inherently subjective and may be subject to review and challenge by various government agencies.

3a9dfef0-90e6-41fe-86db-5859093a0dcb

There has also been enhanced scrutiny by governments on reimbursement support offerings, clinical education programs and promotional speaker programs.

b281bc0f-3325-4776-accf-39c72e4d925e

generic manufacturers have sought, and may continue to seek, FDA approval to market generic versions of GILEAD SCIENCES INC's products.

b50ac4b6-cdef-4075-b37e-c43a97e9073d

Generic versions may lead toMarket share and price erosion.

4d82d1e5-a318-4513-93ad-c9ca027aa353

GIlead SCiENCes INC rely on unpatented trade secrets and improvements, internal know-how and technological innovation.

7c61dac1-e28e-460c-8900-30baf179c960

GILEAD SCIENCES INC are involved in a number of litigation, investigation and other dispute-related matters.

f2442723-643c-40ae-b430-ea35f9416c3d

The testing, manufacturing, marketing and use of commercial products involve substantial risk of product liability claims.

ec784bd6-9d8a-46f9-acf6-5c38077b4321

to adversely affect certain of GILEADS' clinical trials.

7daf4139-8d14-49a8-a210-04c87573fefa

The pandemic has limited patients’ ability or willingness to access and seek care from healthcare providers and initiate new therapies, which has resulted in lower demand for GILEAD SCIENCES INC's products.

6723e9b0-20ca-4e3b-8926-7058385c95f7

On-site employees testing positive for COVID-19 could lead to mandatory quarantines and potential site shutdowns.

52d62ac9-df0a-4d73-b27a-cebe096a622f

GILEADS INC are subject to the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws.

21f28717-bff2-4418-8564-48ee98058eaf

The company's international operations are heavily regulated and require significant interaction with foreign officials.

54dd53a4-a521-413a-84c3-4ff2d9dfbdbd

There is uncertainty concerning any changes in the laws and regulations governing the conduct of clinical trials and marketing of medicinal products.

be8ab4e0-a423-4352-9f81-70baa1135075

GILEad's insurance may not be sufficient in type or amount to cover the losses that may result from an interruption or breach of its systems.

56b19e7c-eafd-4e5b-ab4b-2ac82773e1f4

Changes to U.S. immigration and work authorization laws and regulations could make it more difficult for employees to work in or transfer to GIlead SCiENCes INC.

fd200083-ff17-4bf9-81c0-6fea8d84bff3

GILEAD SCIENCES INC have engaged in, and may in the future engage in,.

8c05dae1-1bf1-42de-9fc2-333196ac5b5b

such transactions as part of its business strategy.

07f5b3bc-d75b-492c-a968-622c1237aa98

Changes in GIlead SCiENCes INC's effective income tax rate could reduce GILEADS' earnings.

4e1bf859-f876-449a-b674-5f49a77f6a5c

Additional indebtedness and a lower cash balance could result in a downgrade of GILAD'S credit ratings.

52eacd98-65dc-4c33-a152-5140f60d76f2

GILEAD SCIENCES, INC. may or may not be able to accurately predict, materially and adversely affect its business and operations.

4ade7612-ac30-42b7-8530-32e398c35199

Certain of GIlead's products subject the company to additional or heightened risks.

b1591b10-2104-41f8-9079-383c34648165

A high rate of failure is inherent in the discovery and development of new products.

8fe628d4-33c2-4b1d-afeb-461a7d68b9bb

Federal and state budget pressures, as well as the grant cycles for state funds, may cause purchasing patterns to not reflect patient demand.

79dfb047-5c0c-4db8-818d-4b75c08b5f1a

The launch of commercially successful products is necessary to grow GIleadSCIENES's business.

e88aa86c-e481-4183-a80d-a7c1cf15c1f0

GIlead SCiENCes, Inc. sell and distribute most of its products in the United States exclusively through the wholesale channel.

50bc2d38-a7a1-45e9-aaf2-8e9bec9ee06d

Successful commercialization depends, in part, on the availability of third-party payer reimbursement for the cost of such products.

f0cea55c-d4c7-43b5-b3a8-aa1847f71099

In the United States, the volume of drug pricing-related bills has dramatically increased in recent years.

21afe251-cfce-4989-a919-0cdb42ca0f10

Changes to the 340B program or the Medicaid program at the federal or state level could have a material adverse effect on GILEAD SCIENCES, INC.

a7e62855-48d9-480f-844c-0fb889585c72

In the EU, there are barriers to reimbursement in individual countries that could limit the uptake of Yescarta and Tecartus.

4e2aeb2f-f727-4f9c-a4ea-0399a9eea83e

Prices for GILEAD SCIENCES, INC.'s products are based on local market economics and competition and sometimes differ from country to country.

c715edcc-79b8-4e35-8840-19c1e3de43dc

Third parties have illegally distributed and sold, and may continue to illegally distribute and sell, illegally diverted and counterfeit versions of Gilead’s medicines.

b88ef0f9-07db-407a-8236-9dc25a20b650

GIlead SCiENCes, Inc. face numerous risks and uncertainties with its clinical trials that could result in delays or prevent completion of the development and approval of its product candidates.

d011b7a5-0001-4a43-8562-afa00dc12259

The company may be unable to recoup the significant RD and Clinical trial expenses incurred in 2022.

6003e31e-8d96-4cb4-8105-1371ccf8a438

Manufacturing issues may cause delays in clinical trials and applications for regulatory approval.

dde756ac-d336-4bf1-978a-39b3a55e05f5

Problems with any single suppliers or facilities depend on, including in the event of a disaster.

aef8d1a0-ef86-4b55-b3a9-ef4e3cb4e74d

A significant portion of the raw materials and intermediates used to manufacture GILEAD SCIENCES, INC.'s antiviral products are supplied by third-party manufacturers and corporate partners outside the United States.

052181a2-8b4c-4271-aa21-3b7e7a2356e3

Failure to obtain broad approvals on a timely basis or to maintain compliance could delay or halt commercialization of GIleads' products.

11ac0fed-f1a0-4ba3-8b35-268fded9c498

It is uncertain if any products, once launched, will have a commercially successful existence.

ab420169-0b9e-4047-89b3-14f303c4e54e

The health care industry is subject to various federal, state and international laws and regulations.

90166f2e-9967-44be-baa5-e14228a80e4a

The resulting impact on GILEAD SCIENCES, INC.'s business is uncertain and could be material.

22c2abcb-2d29-4bd9-a880-0a26e7d29286

There has also been enhanced scrutiny by governments on reimbursement and other patient support offerings.

8eca8cec-f4fa-4aa3-bed2-02c7ce6954c9

Generic manufacturers have sought, and may continue to seek, FDA approval to market generic versions of GILEADS' products.

1fcf2538-3efa-475d-8ab4-db79486a0888

GIleads rely on unpatented trade secrets and improvements in internal know-how and technological innovation.

4b40d611-f6b2-4765-9701-ff79cc040ad2

For a description of the Company's pending patent litigation, see Note 14.

74760399-f8a7-4571-99a6-f2af02553ab8

GIleads is involved in a number of litigation, investigation and other dispute-related matters that require GILEADS to expend substantial internal and financial resources.

5abce5d8-cd65-4d27-9199-db686f41b01d

The testing, manufacturing, marketing and use of GILade's commercial products involve substantial risk of product liability claims.

a43dc791-978d-4c78-9fc9-8f19757e3fc1

GILeade is monitoring anumber of risks related to COVID-19.

2c0205c1-201c-4b7e-9861-7601657c4f8e

The pandemic has adversely affected and may continue to adversely affect certain of GILEAD SCIENCES, INC.'s clinical trials.

d5cc5cb4-d4d9-4de7-b019-ff86725092de

For ongoing trials, clinical trial sites have imposed restrictions on patient visits to limit risks of possible COVID-19 exposure.

b3899745-d23c-4f3a-bdf9-fe504ee64b93

There is also a risk that closures at clinical sites may be necessary.

bb125b05-4913-4384-a4e5-4c8cfe22d5e5

The pandemic has also amplified many of the other risks described throughout the "Risk Factors" section of this Annual Report on Form 10-K. Inflation and interest rate fluctuations could also adversely impact the company's financial results.

dffbd76c-ad8d-402e-9604-630e44c50742

It is possible that certain practices may be challenged under the U.S. Foreign Corrupt Practices Act.

947a9347-e93c-46c1-9443-4e36e7e51718

Institutional and individual investors are increasingly using ESG screening criteria to determine whether Gilead qualifies for inclusion in their investment portfolios.

79312b8e-6f90-4045-996c-b86f868cb704

Failure to achieve any goal or objective, including with respect to environmental and diversity initiatives, is subject to numerous risks, many of which are outside of GIlead SCiENCes, Inc.'s control.

2e9a64c3-3646-4839-8b2b-c2ee55ba8380

There is a great deal of uncertainty regarding the success of GILEAD SCIENCES, INC. Cybersecurity incidents are increasing in their frequency, sophistication and intensity.

4a4ec1a5-54d2-4850-8b15-4e73afaf4b4a

Significant cybersecurity incidents could give rise to legal liability and regulatory action under data protection and privacy laws.

6b9f3bd2-913a-4954-b67e-9c8759fc1137

There is no assurance that GIlead SCiENCes, Inc. will exercise its option right.

d9215cdc-b28d-4618-b692-171cbd9d3d9d

The products, intellectual property and technologies that are acquired or licensed may not be successful or may require significantly greater resources and investments than anticipated.

811201ff-d592-41ff-865d-f1478aa2c498

Additional indebtedness and a lower cash balance could result in a downgrade of GIL's credit ratings.

3f6c442c-2ca3-49a1-9760-60f84d3ddf32

GILEAD SCIENCES, INC. may be adversely affected by the resolution of one or more of these exposures in any reporting period.

11d542a5-aa1b-4065-bbff-b2c3e7e38997

There are differing interpretations of tax laws and regulations and, as a result, significant disputes may arise.

20dd8ffc-a751-4b9d-bf23-a5da570691c9